Navigation Links
Endo Pharmaceuticals Receives FDA Priority Review for New Formulation of Long-Acting Oxymorphone Designed to be Crush Resistant
Date:9/22/2010

CHADDS FORD, Pa., Sept. 22 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced that it recently received notification from the U.S. Food and Drug Administration (FDA) that Endo's new drug application (NDA) for its new oral formulation of long-acting oxymorphone, which is designed to be crush resistant, has been granted priority review status.  The FDA has set the action date under the Prescription Drug User Fee Act (PDUFA) for Jan. 7, 2011.

This new oxymorphone formulation is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. It is a tablet formulation designed to resist crushing, breaking, powdering or pulverizing.  

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiary HealthTronics Inc., please visit www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... Oxybutynin Hydrochloride Industry, 2009-2019 is a professional ... Chinese Oxybutynin Hydrochloride industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Oxybutynin Hydrochloride listing their ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... , , VIENNA, Va. , ... , a late-stage oncology company and a developer of vaccines ... the appointment of Todd S. Burkhart as Vice ...  Mr. Burkhart has over 30 years of experience in the ...
... , Jan. 14 Span-America Medical Systems, Inc. ... its conference call on Friday, January 29, 2010 , ... be released after the regular close of trading the preceding ... be available online at www.spanamerica.com under investor relations ...
Cached Medicine Technology:CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations 2Span-America Announces First Quarter Conference Call On The Internet 2
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... -- More states are passing legislation permitting or requiring ... any child having a severe allergic reaction. Epinephrine ... reaction that can lead to throat swelling, breathing difficulties, ... In people with severe allergies to certain ... or certain drugs, anaphylaxis can occur within moments of ...
(Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:A better way to track emerging cell therapies using MRIs 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2
... Inc's brand cleansing solution has been linked to a severe ... Optometry doctors in the U.S have urged contact lens wearers ... Bausch & Lomb Inc. has stopped shipping ... following warnings from the U.S. Food and Drug Administration (FDA) ...
... than 1lb 6oz. He was so weak that he needed life ... he lived and grew stronger. //Even his mother Donna Morgan who ... be given blood transfusions to recover. ,Now the mother ... helped them, they are launching a campaign to fill the worryingly ...
... from far but far from good! A city that has ... life// , might not be promoting feelings of well-being in ... happen to be a highly distressed lot compared to the ... cause of distress, opining that nearly one out of seven ...
... Ontario plans to revamp the drug system. Health Minister ... to improve the drug program//. He also said that ... drug system transparent and sustainable. They will also speed ... voices are heard. The taxpayers have not received fair ...
... in the April issue of IJCP, the International Journal ... of cases of invasive// pneumococcal diseases (IPD) like meningitis ... still only vaccinate selected at-risk groups against IPD. ... vaccination of infants and young children reduces their risk ...
... obesity is due at least in part to an ... when to stop eating, and a protein more recently// ... protein (CRP) not only binds to leptin but its ... The results may help explain why obese people have ...
Cached Medicine News:Health News:Promotion of Pneumococcal Vaccine Slow in Europe 2Health News:Promotion of Pneumococcal Vaccine Slow in Europe 3Health News:Researchers Identify The Cause To Obesity 2Health News:Researchers Identify The Cause To Obesity 3
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... Clopidogrel Assay measures changes in platelet ... Clopidogrel (Plavix). It uses a specific ... clopidogrel inhibits. The assay has not ... the assay is available for Research ...
Medicine Products: